The AI (Artificial Intelligence)-driven COVID-19 drug discovery is gaining increased popularity in the respiratory virus infection drugs market. Since the coronavirus has become an international health concern, there has been an unprecedented demand for drugs and vaccines. As such, AI holds promising potentials in quick identification of COVID-19 drugs. Thus, companies in the respiratory virus infection drugs market are collaborating with scientists and researchers to predict drugs and peptides that can be used as therapeutic medication for coronavirus treatment.
Pharmaceutical companies are increasing efforts to predict drugs directly from the sequences of infected patients, since they have a better affinity with the target. However, companies need to accelerate their testing capabilities in order to verify safety and feasibility to combat COVID-19. Intelligent algorithms based on machine learning (ML) and Big Data are supporting molecular applications.
To know the scope of our report Get a Sample on Respiratory Virus Infection Drugs Market
The respiratory virus infection drugs market is expected to surpass a value of US$ 82.4 Bn by the end of 2030. However, individuals are becoming increasingly aware about the disadvantages and side effects of influenza drugs, namely favipiravir and baloxavir. Pharma companies need to address low solubility of favipiravir in aqueous media, which may reduce its efficacy in vitro. This indicates that pharma companies need to increase their R&D activities to prevent adverse events of drugs.
Pharma companies are focusing on discoveries in influenza virus polymerase complex. It has been found that influenza viruses are severe human pathogens that pose as a persistent threat to public health. Hence, companies in the respiratory virus infection drugs market are capitalizing on this issue to increase their R&D in influenza virus polymerase complex.
Get a glimpse of the in-depth analysis through our Report Brochure
Companies in the respiratory virus infection drugs market are increasing their focus in nanomaterials designed for antiviral drug delivery of adenovirus infection. This has become important, since respiratory virus infections have become a global health problem causing a significant amount of mortality and morbidity in individuals. Emerging drug resistance and constant viral replication have led to the demand for nanotechnology in antiviral therapies, as nanomaterials offer unique physic-chemical properties ideal for the treatment of adenovirus infection.
Different nanomaterials such as nanosheres, liposomes, nanoparticles, nanogels, and the likes hold promising potentials for efficacious drug administration in order to improve patient outcomes. Companies in the respiratory virus infection drugs market are innovating in nanosuspensions and nanoemulsions to enable drug delivery of unique antiviral agents with prospects in clinical practice.
The COVID-19 pandemic has brought startups in the respiratory virus infection drugs market under great emphasis. For instance, Vir Biotechnology— a specialist in immune therapeutics, is leveraging the advantages of AI and ML in influenza drug development. It has been found that infectious diseases have increased resistance to antibiotics. Startups in the respiratory virus infection drugs market are capitalizing on this opportunity to integrate AI and ML in common cold and influenza drug development.
In order to broaden their revenue streams, the U.S.-based tech startups are working on solutions to address antibiotic resistance in certain strains of influenza A, SARS-CoV-2, and tuberculosis. They are adopting a multi-program and multi-platform approach to develop successful candidates in order to tackle antibiotic resistance. Manufacturers are innovating in antibody platforms and T cell platforms to isolate rare antibodies and use them to boost the immune system.
The respiratory syncytial virus (RSV) is being associated with limited treatment options, resulting in millions of hospitalizations per year. Palivizumab, a monoclonal antibody, is considered as the gold standard for prophylaxis in high-risk infants. However, palivizumab and ribavirin are prone to limited efficacy and significant safety concerns. Hence, manufacturers in the respiratory virus infection drugs market are increasing their research in direct acting antiviral agents (DAAs) to target key steps in the viral life cycle.
It has been found that DAAs are producing landmark clinical studies, which involve nucleoside inhibitors. On the other hand, non-nucleoside inhibitors of replication are being reviewed in addition to inhibitors of other mechanisms. As such, pharma companies in the respiratory virus infection drugs market are taking giant strides in R&D pertaining to viral proteins or host cell factors for inhibition of viral replication.
In vitro and in vivo model systems of the RSV disease are being highlighted in order to create novel drug targets. Companies in the respiratory virus infection drugs market are expanding their treatment options for lower respiratory tract infections (LRTI). For instance, Sanofi— a global biopharmaceutical company, announced that it received positive Phase 2b trial for nirsevimab, since it showed significant decline in medically attended lower respiratory tract infections. This involves increased hospitalization caused due to RSV in healthy preterm infants.
Single dose monoclonal antibodies are found to significantly reduce medically attended RSV LRTI infants through the full RSV season. Nirsevimad is being highly publicized as an extended half-life RSV monoclonal antibody. Companies are entering into strategic partnerships to innovate in treatments for LRTI in infants. Nirsevimab is gaining popularity as the new standard of care by offering innovative immunization for immediate and sustained protection for all infants during the first season of RSV.
Companies in the respiratory virus infection drugs market are increasing their production capabilities for anti-influenza drugs. Pharma companies in the respiratory virus infection drugs market are developing inhibitors of influenza virus polymerase, which are among the most promising types of drugs. Favipiravir and boloxavir are being approved for influenza treatment in Japan and the U.S. It has been found that favipiravir effectively and selectively inhibits the RNA dependent RNA polymerase of RNA viruses.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Sustainable pharmaceutical innovations in COVID-19 treatment hold promising potentials for other infectious diseases. Thus, the respiratory virus infection drugs market is estimated to grow at a healthy CAGR of ~7% during the assessment period. However, the issue of drug resistance in case of constant mutation of influenza virus is impacting market growth. Hence, pharma companies should conduct a sustained surveillance of the drug susceptibility of influenza viruses. Moreover, limited efficacy of influenza vaccines and drug resistance from small molecule antiviral drugs have led to the demand for new antivirals with novel mode of action.
Respiratory Virus Infection Drugs Market – Segmentation
| Drug Type |
|
| Infection Type |
|
| Route of Administration |
|
| Mode of Purchase |
|
| Distribution Channel |
|
| Region |
|
Respiratory virus infection drugs market is expected to surpass a value of US$ 82.4 Bn by the end of 2030
Respiratory virus infection drugs market is projected to expand at a CAGR of ~7% from 2020 to 2030
Respiratory virus infection drugs market is driven by increase in focus on research & development, steady rise in prevalence of respiratory virus infections across the globe
North America dominated the global respiratory virus infection drugs market and the trend is anticipated to continue during the forecast period
Key players in the global respiratory virus infection drugs market include GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Respiratory Virus Infection Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, 2018–2030
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Pipeline Analysis (asthma and COPD)
5.3. Regulatory Scenario
5.4. Disease Prevalence Rate in Key Countries
5.5. Key Market Events
5.6. COVID-19 Pandemic Impact on Industry
6. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2018–2030
6.3.1. Antibiotics
6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.3. Cough Suppressants
6.3.4. Nasal Decongestants
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Infection Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Infection Type, 2018–2030
7.3.1. Respiratory Syncytial Virus (RSV) Infection
7.3.2. Influenza Virus Infection
7.3.3. Parainfluenza Virus Infection
7.3.4. Adenovirus Infection
7.3.5. Rhinovirus Infection
7.3.6. Others
7.4. Market Attractiveness Analysis, by Infection Type
8. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2018–2030
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Mode of Purchase
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Mode of Purchase, 2018–2030
9.3.1. Prescription-based Drugs
9.3.2. Over-the-Counter Drugs
9.4. Market Attractiveness Analysis, by Mode of Purchase
10. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Distribution Channel
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by Distribution Channel, 2018–2030
10.3.1. Hospital Pharmacies
10.3.2. Drug Stores
10.3.3. Retail Pharmacies
10.3.4. Clinics
10.3.5. Others
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Respiratory Virus Infection Drugs Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America Respiratory Virus Infection Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2018–2030
12.2.1. Antibiotics
12.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.2.3. Cough Suppressants
12.2.4. Nasal Decongestants
12.2.5. Others
12.3. Market Value Forecast, by Infection Type, 2018–2030
12.3.1. Respiratory syncytial viruses (RSV) Infection
12.3.2. Influenza Virus Infection
12.3.3. Parainfluenza Virus Infection
12.3.4. Adenovirus Infection
12.3.5. Rhinovirus Infection
12.3.6. Others
12.4. Market Value Forecast, by Route of Administration, 2018–2030
12.4.1. Oral
12.4.2. Parenteral
12.5. Market Value Forecast, by Mode of Purchase, 2018–2030
12.5.1. Prescription-based Drugs
12.5.2. Over-the-Counter Drugs
12.6. Market Value Forecast, by Distribution Channel, 2018–2030
12.6.1. Hospital Pharmacies
12.6.2. Drug Stores
12.6.3. Retail Pharmacies
12.6.4. Clinics
12.6.5. Others
12.7. Market Value Forecast, by Country, 2018–2030
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Drug Type
12.8.2. By Infection Type
12.8.3. By Route Of Administration
12.8.4. By Mode of Purchase
12.8.5. By Distribution Channel
12.8.6. By Country
13. Europe Respiratory Virus Infection Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2018–2030
13.2.1. Antibiotics
13.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.2.3. Cough Suppressants
13.2.4. Nasal Decongestants
13.2.5. Others
13.3. Market Value Forecast, by Infection Type, 2018–2030
13.3.1. Respiratory Syncytial Virus (RSV) Infection
13.3.2. Influenza Virus Infection
13.3.3. Parainfluenza Virus Infection
13.3.4. Adenovirus Infection
13.3.5. Rhinovirus Infection
13.3.6. Others
13.4. Market Value Forecast, by Route of Administration, 2018–2030
13.4.1. Oral
13.4.2. Parenteral
13.5. Market Value Forecast, by Mode of Purchase, 2018–2030
13.5.1. Prescription-based Drugs
13.5.2. Over-the-Counter Drugs
13.6. Market Value Forecast, by Distribution Channel, 2018–2030
13.6.1. Hospital Pharmacies
13.6.2. Drug Stores
13.6.3. Retail Pharmacies
13.6.4. Clinics
13.6.5. Others
13.7. Market Value Forecast, by Country/Sub-region, 2018–2030
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Drug Type
13.8.2. By Infection Type
13.8.3. By Route Of Administration
13.8.4. By Mode of Purchase
13.8.5. By Distribution Channel
13.8.6. By Country/Sub-region
14. Asia Pacific Respiratory Virus Infection Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Type, 2018–2030
14.2.1. Antibiotics
14.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.2.3. Cough Suppressants
14.2.4. Nasal Decongestants
14.2.5. Others
14.3. Market Value Forecast, by Infection Type, 2018–2030
14.3.1. Respiratory Syncytial Virus (RSV) Infection
14.3.2. Influenza Virus Infection
14.3.3. Parainfluenza Virus Infection
14.3.4. Adenovirus Infection
14.3.5. Rhinovirus Infection
14.3.6. Others
14.4. Market Value Forecast, by Route Of Administration, 2018–2030
14.4.1. Oral
14.4.2. Parenteral
14.5. Market Value Forecast, by Mode of Purchase, 2018–2030
14.5.1. Prescription-based Drugs
14.5.2. Over-the-Counter Drugs
14.6. Market Value Forecast, by Distribution Channel, 2018–2030
14.6.1. Hospital Pharmacies
14.6.2. Drug Stores
14.6.3. Retail Pharmacies
14.6.4. Clinics
14.6.5. Others
14.7. Market Value Forecast, by Country/Sub-region, 2018–2030
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Drug Type
14.8.2. By Infection Type
14.8.3. By Route of Administration
14.8.4. By Mode of Purchase
14.8.5. By Distribution Channel
14.8.6. By Country/Sub-region
15. Latin America Respiratory Virus Infection Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Type, 2018–2030
15.2.1. Antibiotics
15.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
15.2.3. Cough Suppressants
15.2.4. Nasal Decongestants
15.2.5. Others
15.3. Market Value Forecast, by Infection Type, 2018–2030
15.3.1. Respiratory Syncytial Virus (RSV) Infection
15.3.2. Influenza Virus Infection
15.3.3. Parainfluenza Virus Infection
15.3.4. Adenovirus Infection
15.3.5. Rhinovirus Infection
15.3.6. Others
15.4. Market Value Forecast, by Route of Administration, 2018–2030
15.4.1. Oral
15.4.2. Parenteral
15.5. Market Value Forecast, by Mode of Purchase, 2018–2030
15.5.1. Prescription-based Drugs
15.5.2. Over-the-Counter Drugs
15.6. Market Value Forecast, by Distribution Channel, 2018–2030
15.6.1. Hospital Pharmacies
15.6.2. Drug Stores
15.6.3. Retail Pharmacies
15.6.4. Clinics
15.6.5. Others
15.7. Market Value Forecast, by Country/Sub-region, 2018–2030
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Drug Type
15.8.2. By Infection Type
15.8.3. By Route of Administration
15.8.4. By Mode of Purchase
15.8.5. By Distribution Channel
15.8.6. By Country/Sub-region
16. Middle East & Africa Respiratory Virus Infection Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Type, 2018–2030
16.2.1. Antibiotics
16.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
16.2.3. Cough Suppressants
16.2.4. Nasal Decongestants
16.2.5. Others
16.3. Market Value Forecast, by Infection Type, 2018–2030
16.3.1. Respiratory Syncytial Virus (RSV) Infection
16.3.2. Influenza Virus Infection
16.3.3. Parainfluenza Virus Infection
16.3.4. Adenovirus Infection
16.3.5. Rhinovirus Infection
16.3.6. Others
16.4. Market Value Forecast, by Route of Administration, 2018–2030
16.4.1. Oral
16.4.2. Parenteral
16.5. Market Value Forecast, by Mode of Purchase, 2018–2030
16.5.1. Prescription-based Drugs
16.5.2. Over-the-Counter Drugs
16.6. Market Value Forecast, by Distribution Channel, 2018–2030
16.6.1. Hospital Pharmacies
16.6.2. Drug Stores
16.6.3. Retail Pharmacies
16.6.4. Clinics
16.6.5. Others
16.7. Market Value Forecast, by Country/Sub-region, 2018–2030
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Drug Type
16.8.2. By Infection Type
16.8.3. By Route of Administration
16.8.4. By Mode of Purchase
16.8.5. By Distribution Channel
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (by tier and size of companies)
17.2. Market Share Analysis/Ranking, by Company, 2019
17.3. Company Profiles
17.3.1. GlaxoSmithKline plc
17.3.1.1. Company Overview
17.3.1.2. Company Financials
17.3.1.3. Growth Strategies
17.3.1.4. SWOT Analysis
17.3.2. Merck & Co., Inc.
17.3.2.1. Company Overview
17.3.2.2. Company Financials
17.3.2.3. Growth Strategies
17.3.2.4. SWOT Analysis
17.3.3. AstraZeneca
17.3.3.1. Company Overview
17.3.3.2. Company Financials
17.3.3.3. Growth Strategies
17.3.3.4. SWOT Analysis
17.3.4. Boehringer Ingelheim International GmbH
17.3.4.1. Company Overview
17.3.4.2. Company Financials
17.3.4.3. Growth Strategies
17.3.4.4. SWOT Analysis
17.3.5. F. Hoffmann-La Roche Ltd.
17.3.5.1. Company Overview
17.3.5.2. Company Financials
17.3.5.3. Growth Strategies
17.3.5.4. SWOT Analysis
17.3.6. Teva Pharmaceutical Industries Ltd.
17.3.6.1. Company Overview
17.3.6.2. Company Financials
17.3.6.3. Growth Strategies
17.3.6.4. SWOT Analysis
17.3.7. Sanofi
17.3.7.1. Company Overview
17.3.7.2. Company Financials
17.3.7.3. Growth Strategies
17.3.7.4. SWOT Analysis
17.3.8. Cipla, Inc.
17.3.8.1. Company Overview
17.3.8.2. Company Financials
17.3.8.3. Growth Strategies
17.3.8.4. SWOT Analysis
17.3.9. CHIESI Farmaceutici S.p.A.
17.3.9.1. Company Overview
17.3.9.2. Company Financials
17.3.9.3. Growth Strategies
17.3.9.4. SWOT Analysis
17.3.10. Orion Corporation
17.3.10.1. Company Overview
17.3.10.2. Growth Strategies
17.3.10.3. SWOT Analysis
List of Tables
Table 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 02: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 03: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 04: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 05: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 06: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Region, 2018–2030
Table 07: North America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country, 2018–2030
Table 08: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 09: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 10: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 11: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 12: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 13: Europe Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 14: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 15: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 16: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 17: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 18: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 19: Asia Pacific Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 20: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 21: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 22: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 23: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 24: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 25: Latin America Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 26: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 27: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 28: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 29: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 30: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
Table 31: Middle East & Africa Respiratory Virus Infection Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2018–2030
Table 32: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Drug Type, 2018–2030
Table 33: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Infection Type, 2018–2030
Table 34: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Route of Administration, 2018–2030
Table 35: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Mode of Purchase, 2018–2030
Table 36: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2018–2030
List of Figures
Figure 01: Global Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast, 2018–2030
Figure 02: Global Respiratory Virus Infection Drugs Market Value Share, by Drug Type, 2019
Figure 03: Global Respiratory Virus Infection Drugs Market Value Share, by Infection Type, 2019
Figure 04: Global Respiratory Virus Infection Drugs Market Value Share, by Route of Administration, 2019
Figure 05: Global Respiratory Virus Infection Drugs Market Value Share, by Mode of Purchase, 2019
Figure 06: Global Respiratory Virus Infection Drugs Market Value Share, by Distribution Channel, 2019
Figure 07: Global Respiratory Virus Infection Drugs Market Value Share, by Region, 2019
Figure 08: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Drug Type, 2019 and 2030
Figure 09: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030
Figure 10: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Antibiotics, 2018–2030
Figure 11: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2018–2030
Figure 12: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Cough Suppressants, 2018–2030
Figure 13: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Nasal Decongestants, 2018–2030
Figure 14: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030
Figure 15: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Infection Type, 2019 and 2030
Figure 16: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030
Figure 17: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Respiratory Syncytial Virus (RSV) Infection, 2018–2030
Figure 18: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Influenza Virus Infection, 2018–2030
Figure 19: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Parainfluenza Virus Infection, 2018–2030
Figure 20: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Adenovirus Infection, 2018–2030
Figure 21: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Rhinovirus Infection, 2018–2030
Figure 22: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030
Figure 23: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Route of Administration, 2019 and 2030
Figure 24: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 25: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Oral, 2018–2030
Figure 26: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Parenteral, 2018–2030
Figure 27: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Mode of Purchase, 2019 and 2030
Figure 28: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030
Figure 29: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Prescription-based Drugs, 2018–2030
Figure 30: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Over-the-Counter Drugs, 2018–2030
Figure 31: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Distribution Channel, 2019 and 2030
Figure 32: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 33: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Hospital Pharmacies, 2018–2030
Figure 34: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Drug Stores, 2018–2030
Figure 35: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Retail Pharmacies, 2018–2030
Figure 36: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Clinics, 2018–2030
Figure 37: Global Respiratory Virus Infection Drugs Market Revenue (US$ Mn), by Others, 2018–2030
Figure 38: Global Respiratory Virus Infection Drugs Market Value Share Analysis, by Region, 2019 and 2030
Figure 39: Global Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Region
Figure 40: North America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 41: North America Respiratory Virus Infection Drugs Market Value Share (%), by Country, 2019 and 2030
Figure 42: North America Respiratory Virus Infection Drugs Market Attractiveness, by Country, 2020–2030
Figure 43: North America Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030
Figure 44: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030
Figure 45: North America Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030
Figure 46: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030
Figure 47: North America Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 48: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 49: North America Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030
Figure 50: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030
Figure 51: North America Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 52: North America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 53: Europe Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 54: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 55: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 56: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030
Figure 57: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030
Figure 58: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030
Figure 59: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030
Figure 60: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 61: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 62: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030
Figure 63: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030
Figure 64: Europe Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 65: Europe Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 66: Asia Pacific Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 67: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 68: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 69: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030
Figure 70: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030
Figure 71: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030
Figure 72: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030
Figure 73: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 74: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 75: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030
Figure 76: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030
Figure 77: Asia Pacific Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 78: Asia Pacific Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 79: Latin America Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 80: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 81: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 82: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030
Figure 83: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030
Figure 84: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030
Figure 85: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030
Figure 86: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 87: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 88: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030
Figure 89: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030
Figure 90: Latin America Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 91: Latin America Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Figure 92: Middle East & Africa Respiratory Virus Infection Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2030
Figure 93: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Country/Sub-region, 2019 and 2030
Figure 94: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Country/Sub-region, 2020–2030
Figure 95: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Drug Type, 2019 and 2030
Figure 96: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Drug Type, 2020–2030
Figure 97: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Infection Type, 2019 and 2030
Figure 98: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Infection Type, 2020–2030
Figure 99: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Route of Administration, 2019 and 2030
Figure 100: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Route of Administration, 2020–2030
Figure 101: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Mode of Purchase, 2019 and 2030
Figure 102: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Mode of Purchase, 2020–2030
Figure 103: Middle East & Africa Respiratory Virus Infection Drugs Market Value Share (%), by Distribution Channel, 2019 and 2030
Figure 104: Middle East & Africa Respiratory Virus Infection Drugs Market Attractiveness Analysis, by Distribution Channel, 2020–2030
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Respiratory Virus Infection Drugs Market
*86 figures and 60 tables includes